Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive factors of response to omalizumab and mepolizumab in severe allergic and eosinophilic asthma
2017-002473-19Phase 4Active
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of omalizumab and mepolizumab in severe asthma (2 arms), sponsored by Cliniques universitaires Saint-Luc. Started Mar 2018; status: active.
02
Drugs
omalizumabmepolizumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2017-002473-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002473-19.